<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40300">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02057523</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0764</org_study_id>
    <nct_id>NCT02057523</nct_id>
  </id_info>
  <brief_title>Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients</brief_title>
  <official_title>Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Questcor Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the benefit of ACTH (Acthar) in reducing proteinuria
      associated with transplant glomerulopathy in non-diabetic kidney transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>50% Reduction in Proteinuria or Proteinuria &lt; 150mg/day</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>25% Reduction in the MDRD eGFR</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Proteinuria</condition>
  <condition>Transplant Glomerulopathy</condition>
  <arm_group>
    <arm_group_label>Acthar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acthar 80mg twice weekly for 6 months.  If endpoint is not reached, duration may be increased to 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar</intervention_name>
    <description>Those interested will be started on Acthar 80mg twice weekly for 6 months.  Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40mg twice weekly.  Those with major adverse effects such as allergy or infection will discontinue the medication.  If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.</description>
    <arm_group_label>Acthar</arm_group_label>
    <other_name>Repository Corticotropin Hormone</other_name>
    <other_name>Acthar Gel</other_name>
    <other_name>Adrenocorticotropic Hormone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Kidney transplant recipients with confirmed transplant glomerulopathy on kidney
             biopsy.

          -  Failed standard therapy (&gt;25% reduction in proteinuria) including maximum use of an
             ACE inhibitor, ARB, or aldosterone blocker with a goal blood pressure less than
             130/80 and optimization of their immunosuppression

        Exclusion Criteria:

          -  Diabetes
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjeev Akkina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanjeev Akkina, MD</last_name>
    <phone>312-996-8075</phone>
    <email>sakkina@uic.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maya Campara, PharmD</last_name>
    <phone>312-996-0897</phone>
    <phone_ext>1</phone_ext>
    <email>mcampa4@uic.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanjeev Akkina, MD</last_name>
      <phone>312-996-8075</phone>
      <email>sakkina@uic.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maya Campara, PharmD</last_name>
      <phone>312-996-0897</phone>
      <email>mcampa4@uic.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjeev Akkina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 5, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Sanjeev Akkina</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Beta-Endorphin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
